Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 1/2012

01-01-2012 | Article

Evaluation of matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry for identification of Candida parapsilosis, C. orthopsilosis and C. metapsilosis

Authors: I. Quiles-Melero, J. García-Rodríguez, A. Gómez-López, J. Mingorance

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 1/2012

Login to get access

Abstract

We have evaluated matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry for the rapid identification of Candida parapsilosis, C. orthopsilosis and C. metapsilosis. A total of 103 isolates, including reference strains and clinical isolates, were identified by pyrosequencing of the ITS1 region and then assay by MALDI-TOF mass spectrometry. Concordance between the two methods was 100%, showing that MALDI-TOF may be useful as a rapid and reliable method for discrimination of species within the C. parapsilosis group.
Literature
1.
Levin AS, Costa SF, Mussi NS, Basso SI, Sinto SI, Machado SC, Geiger DC, Villares MCB, Schreiber AZ, Barone AA, Branchini MLM (1998) Candida parapsilosis fungaemia associated with implantable and semi-implantable central venous catheters and the hands of healthcare workers. Diagn Microbiol Infect Dis 30:243–249PubMedCrossRef
2.
Lupetti A, Tavanti A, Davini O, Ghelardi E, Corsini I, Merusi A, Boldrini A, Campa M, Senesi S (2002) Horizontal transmission of Candida parapsilosis candidaemia in a neonatal intensive care unit. J Clin Microbiol 40:2363–2369PubMedCrossRef
3.
Kojic EM, Darouiche RO (2004) Candida infections of medical devices. Clin Microbiol Rev 17:255–267PubMedCrossRef
4.
Weems JJ Jr (1992) Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Clin Infect Dis 14:756–766PubMedCrossRef
5.
Lehmann PF, Lin DM, Lasker BA (1992) Genotypic identification and characterization of species and strains within the genus Candida by using random amplified polymorphic DNA. J Clin Microbiol 30:3249–3254PubMed
6.
Lin D, Wu LC, Rinaldi MG, Lehmann PF (1995) Three distinct genotypes within Candida parapsilosis from clinical sources. J Clin Microbiol 33:1815–1821PubMed
7.
Kato M, Ozeki M, Kikuchi A, Kanbe T (2001) Phylogenetic relationship and mode of evolution of yeast DNA topoisomerase II gene in the pathogenic Candida species. Gene 272:275–281PubMedCrossRef
8.
Nosek J, Tomaska L, Rycovska A, Fukuhara H (2002) Mitochondrial telomeres as molecular markers for identification of the opportunistic yeast pathogen Candida parapsilosis. J Clin Microbiol 40:1283–1289PubMedCrossRef
9.
Tavanti A, Davidson AD, Gow NA, Maiden MC, Odds FC (2005) Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 43:284–292PubMedCrossRef
10.
Borman AM, Linton CJ, Oliver D, Palmer MD, Szekely A, Odds FC, Johnson M (2009) Pyrosequencing analysis of 20 nucleotides of internal transcribed spacer 2 discriminates Candida parapsilosis, Candida metapsilosis and Candida orthopsilosis. J Clin Microbiol 47:2307–2310PubMedCrossRef
11.
Lockhart SR, Messer SA, Pfaller MA, Diekema DJ (2008) Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J Clin Microbiol 46:2659–2664PubMedCrossRef
12.
Gómez-López A, Alatruey-Izquierdo A, Rodríguez D, Almirante B, Pahissa A, Rodríguez-Tudela JL, Cuenca-Estrella M, the Barcelona Candidemia Project Study Group (2008) Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of Candidemia in Spain. Antimicrob Agents Chemother 52:1506–1509PubMedCrossRef
13.
Degand N, Carbonnelle E, Dauphin B, Beretti J, Le Bourgeois LM, Semet-Gaudelus C, Segonds BP, Nassif X, Ferroni A (2008) Matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of nonfermenting gram-negative bacilli isolated from cystic fibrosis patients. J Clin Microbiol 46:3361–3367PubMedCrossRef
14.
Marklein G, Josten M, Klanke U, Müller E, Horré R, Maier T, Wenzel T, Kostrzewa M, Bierbaum G, Hoerauf A, Sahl HG (2009) Matrix-assisted laser desorption ionization-time of flight mass spectrometry for fast and reliable identification of clinical yeast isolates. J Clin Microbiol 47:2912–2917PubMedCrossRef
15.
Marinach-Patrice C, Lethuillier A, Marly A, Brossas JY, Gene J, Symoens F (2009) Use of mass spectrometry to identify clinical Fusarium isolates. Clin Microbiol Infect 15:634–642PubMedCrossRef
16.
Seng P, Drancourt M, Gouriet F, La Scola B, Fournier PE, Rolain JM, Raoult D (2009) Ongoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Infect Dis 49:543–551PubMedCrossRef
17.
Stevenson LG, Drake SK, Shea YR, Zelazny AM, Murray PR (2010) Evaluation of matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF) for identification of clinically important yeast species. J Clin Microbiol 48:3482–3486PubMedCrossRef
18.
Cantón E, Espinel-Ingroff A, Pemán J, del Castillo L (2010) In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. Antimicrob Agents Chemother 54:2194–2197PubMedCrossRef
19.
De Toro M, Torres MJ, Maite R, Aznar J (2011) Characterization of Candida parapsilosis complex isolates. Clin Microbiol Infect 17:418–424PubMedCrossRef
20.
Melo AS, Bizerra F, Freymüller E, Arthington-Skaggs BA, Colombo AL (2011) Biofilm production and evaluation of antifungal susceptibility amongst clinical Candida spp. isolates, including strains of the Candida parapsilosis complex. Med Mycol 49:253–262PubMedCrossRef
21.
Orsi CF, Colombari B, Blasi E (2010) Candida metapsilosis as the least virulent member of the 'C. parapsilosis'’ complex. Med Mycol 48:1024–1033PubMedCrossRef
22.
Metadata
Title
Evaluation of matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry for identification of Candida parapsilosis, C. orthopsilosis and C. metapsilosis
Authors
I. Quiles-Melero
J. García-Rodríguez
A. Gómez-López
J. Mingorance
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 1/2012
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-011-1277-z

Other articles of this Issue 1/2012

European Journal of Clinical Microbiology & Infectious Diseases 1/2012 Go to the issue

Review

Candida and invasive candidiasis: back to basics

Article

Virological and molecular characterization of Kaposi’s sarcoma-associated herpesvirus strains from Xinjiang, China

Article

Increases in Australian cutaneous abscess hospitalisations: 1999–2008

Article

Candida glabrata strain relatedness by new microsatellite markers

Editorial

A unifying hypothesis and a single name for a complex globally emerging infection: hantavirus disease

Article

Soluble triggering receptor expressed on myeloid cells in sputum of patients with community-acquired pneumonia or pulmonary tuberculosis: a pilot study
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits